The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain

P Glare, D Walsh, D Sheehan - American Journal of Hospice …, 2006 - journals.sagepub.com
Little information is available about the incidence, prevalence, or severity of morphine side
effects during repeated individualized dosing for chronic cancer pain, although it has been …

Immediate-or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial

P Klepstad, S Kaasa, Å Jystad, B Hval… - Pain, 2003 - journals.lww.com
A titration procedure using immediate-release morphine given 4-hourly is recommended
during start of oral morphine for cancer pain. This recommendation is not based on evidence …

The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine

M Deschamps, PR Band, TG Hislop… - Journal of pain and …, 1992 - Elsevier
We compared the effects of controlled-release and immediate-release morphine
preparations in adult patients with moderate-to-severe cancer pain and report methodologic …

Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use

D Walsh, ML Perin, B McIver - American Journal of Hospice …, 2006 - journals.sagepub.com
Prescribing patterns for parenteral morphine for symptom control in advanced cancer were
studied in 50 consecutive hospital admissions (27 men, 23 women, median age, 62 years) …

[引用][C] Morphine dosages in the management of cancer pain

SA Schug, D Zech, S Grond - Pain, 1990 - No longer published by Elsevier

Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with …

C Quigley, S Joel, N Patel, A Baksh… - Palliative …, 2003 - journals.sagepub.com
Morphine, the recommended drug for the management of moderate to severe cancer pain, is
metabolized predominantly to the glucuronides morphine-6-glucuronide (M6G) and …

The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase'in patients with cancer pain

F De Conno, C Ripamonti, E Fagnoni… - Palliative …, 2008 - journals.sagepub.com
Adequate and rapid pain control is one of the main goals of cancer pain treatment. The
objective of this study was to assess the effect and tolerability of oral normal-release …

Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

G Andersen, NH Jensen, L Christrup… - Palliative …, 2002 - journals.sagepub.com
Background: Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the
two most important metabolites of morphine. Both are pharmacologically active, however …

The efficacy and side effects of continuous infusion intravenous morphine (CIVM) for pain and symptoms due to advanced cancer

P Glare, D Walsh, E Groh… - American Journal of …, 2002 - journals.sagepub.com
Morphine is the strong opioid of choice in the management of moderate-to-severe chronic
cancer pain. The preferred route of administration is oral, in individually titrated doses …

Intravenous titration with morphine for severe cancer pain: report of 28 cases

L Radbruch, G Loick, S Schulzeck, A Beyer… - The Clinical journal …, 1999 - journals.lww.com
Background: In a multicenter study, 28 patients with cancer pain and insufficient pain relief
with analgesic treatment according to step II of the guidelines of the World Health …